N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide

Request For Quotation
N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: Shanghai Hongye Biotechnology Co. Ltd  
Tel: 400-9205774 400-920-5774
Email: sales@glpbio.cn
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: Shanghai Yifei Biotechnology Co. , Ltd.  
Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn

N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide manufacturers
N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide Basic information
Product Name:N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide
Synonyms:N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide;9-Octadecenamide, N-[2-(3,4-dihydroxyphenyl)-1-methylethyl]-, (9Z)-;N-[2-(3,4-dihydroxyphenyl)-1-methylethyl]-9Z-octadecenamide
CAS:1258011-97-0
MF:C27H45NO3
MW:431.65
EINECS:
Product Categories:
Mol File:1258011-97-0.mol
N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide Structure
N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide Chemical Properties
Boiling point 624.5±55.0 °C(Predicted)
density 0.997±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMF: 30 mg/ml; DMSO: 25 mg/ml; Ethanol: 30 mg/ml; Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/ml
pka9.79±0.10(Predicted)
Safety Information
MSDS Information
N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide Usage And Synthesis
DescriptionN-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide binds to the cannabinoid 1 (CB1) receptor with a Ki value of 365 nM in a radioligand binding assay using rat brain homogenate.1 It has an EC50 value of 698 nM for the peroxisome proliferator-activated receptor α (PPARα) in a luciferase reporter assay and, in rats, it decreases food intake. It does not inhibit fatty acid amide hydrolase (FAAH).
UsesOLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD)[1][2].
in vivo

OLHHA (5 mg/kg; i.p.; daily for 15 days) reduces both hepatic lipid accumulation and circulating triglyceride levels[2].

Animal Model:8- to 9-week-old male Zucker rats (genetic obesity)[2]
Dosage:5 mg/kg
Administration:I.p.; daily for 15 days
Result:Reduced the liver fat content and plasma triglyceride levels, and this was accompanied by a general improvement in the profile of plasma parameters related to liver damage in the obese rats, significantly reduced the body weight gain and decreased in the relative expression of CB1 in lean rats.
References1. Almeida, B., Joglar, J., Rojas, M.J.L., et al. Synthesis of fatty acid amides of catechol metabolites that exhibit antiobesity properties. ChemMedChem 4;5(10),1781-1787(2010).
N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide Preparation Products And Raw materials
Tag:N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide(1258011-97-0) Related Product Information
N-(1,1,2,2-tetradeuterio-2-hydroxyethyl)hexadecanamide Palmitoyl Ethanolamide-d4 Linoleoylethanolamide Oleamide Palmitoyl Ethanolamide-d5 Astaxanthin